Thioridazine: resurrection as an antimicrobial agent?
Identifieur interne : 002D55 ( Pmc/Corpus ); précédent : 002D54; suivant : 002D56Thioridazine: resurrection as an antimicrobial agent?
Auteurs : H K R. ThanacoodySource :
- British Journal of Clinical Pharmacology [ 0306-5251 ] ; 2007.
Abstract
The emergence of multiresistant bacterial strains and the continuing burden of infectious disease globally point to the urgent need for novel affordable antimicrobial drugs. Thioridazine is a phenothiazine antipsychotic drug with well-recognized antimicrobial activity, but this property has not been harnessed for clinical use as a result of its central nervous system and cardiac side-effects. The cardiotoxicity of thioridazine has recently been shown to be structurally specific at a molecular level, whereas its antimicrobial properties are shared by a number of phenothiazine analogues. This raises the possibility that its enantiomers or its inactive metabolite, the ring sulphoxide, may act as a lead compound in the future development of antimicrobial drugs to face the new challenges in infectious disease.
Url:
DOI: 10.1111/j.1365-2125.2007.03021.x
PubMed: 17764469
PubMed Central: 2203271
Links to Exploration step
PMC:2203271Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Thioridazine: resurrection as an antimicrobial agent?</title>
<author><name sortKey="Thanacoody, H K R" sort="Thanacoody, H K R" uniqKey="Thanacoody H" first="H K R" last="Thanacoody">H K R. Thanacoody</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">17764469</idno>
<idno type="pmc">2203271</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2203271</idno>
<idno type="RBID">PMC:2203271</idno>
<idno type="doi">10.1111/j.1365-2125.2007.03021.x</idno>
<date when="2007">2007</date>
<idno type="wicri:Area/Pmc/Corpus">002D55</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">002D55</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Thioridazine: resurrection as an antimicrobial agent?</title>
<author><name sortKey="Thanacoody, H K R" sort="Thanacoody, H K R" uniqKey="Thanacoody H" first="H K R" last="Thanacoody">H K R. Thanacoody</name>
</author>
</analytic>
<series><title level="j">British Journal of Clinical Pharmacology</title>
<idno type="ISSN">0306-5251</idno>
<idno type="eISSN">1365-2125</idno>
<imprint><date when="2007">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p>The emergence of multiresistant bacterial strains and the continuing burden of infectious disease globally point to the urgent need for novel affordable antimicrobial drugs. Thioridazine is a phenothiazine antipsychotic drug with well-recognized antimicrobial activity, but this property has not been harnessed for clinical use as a result of its central nervous system and cardiac side-effects. The cardiotoxicity of thioridazine has recently been shown to be structurally specific at a molecular level, whereas its antimicrobial properties are shared by a number of phenothiazine analogues. This raises the possibility that its enantiomers or its inactive metabolite, the ring sulphoxide, may act as a lead compound in the future development of antimicrobial drugs to face the new challenges in infectious disease.</p>
</div>
</front>
</TEI>
<pmc article-type="review-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Clin Pharmacol</journal-id>
<journal-id journal-id-type="publisher-id">bcp</journal-id>
<journal-title>British Journal of Clinical Pharmacology</journal-title>
<issn pub-type="ppub">0306-5251</issn>
<issn pub-type="epub">1365-2125</issn>
<publisher><publisher-name>Blackwell Science Inc</publisher-name>
</publisher>
</journal-meta>
<article-meta><article-id pub-id-type="pmid">17764469</article-id>
<article-id pub-id-type="pmc">2203271</article-id>
<article-id pub-id-type="doi">10.1111/j.1365-2125.2007.03021.x</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject>
</subj-group>
</article-categories>
<title-group><article-title>Thioridazine: resurrection as an antimicrobial agent?</article-title>
</title-group>
<contrib-group><contrib contrib-type="author"><name><surname>Thanacoody</surname>
<given-names>H K R</given-names>
</name>
</contrib>
<aff><institution>Royal Infirmary of Edinburgh</institution>
<addr-line>Edinburgh, UK</addr-line>
</aff>
</contrib-group>
<author-notes><corresp id="cor1"><bold>Correspondence Dr H. K. R. Thanacoody, MD, FRCP(Edin),</bold>
Consultant Physician, Royal Infirmary Edinburgh, 51 Little France Crescent, Edinburgh, UK. <bold>Tel:</bold>
+ 44 13 1242 1293 <bold>Fax:</bold>
+ 44 13 1242 1387 <bold>E-mail:</bold>
<email>ruben.thanacoody@luht.scot.nhs.uk</email>
</corresp>
</author-notes>
<pub-date pub-type="ppub"><month>11</month>
<year>2007</year>
</pub-date>
<pub-date pub-type="epub"><day>31</day>
<month>8</month>
<year>2007</year>
</pub-date>
<volume>64</volume>
<issue>5</issue>
<fpage>566</fpage>
<lpage>574</lpage>
<history><date date-type="received"><day>11</day>
<month>5</month>
<year>2007</year>
</date>
<date date-type="accepted"><day>03</day>
<month>7</month>
<year>2007</year>
</date>
</history>
<copyright-statement>© 2007 The Author; Journal Compilation © 2007 Blackwell Publishing Ltd</copyright-statement>
<copyright-year>2007</copyright-year>
<abstract><p>The emergence of multiresistant bacterial strains and the continuing burden of infectious disease globally point to the urgent need for novel affordable antimicrobial drugs. Thioridazine is a phenothiazine antipsychotic drug with well-recognized antimicrobial activity, but this property has not been harnessed for clinical use as a result of its central nervous system and cardiac side-effects. The cardiotoxicity of thioridazine has recently been shown to be structurally specific at a molecular level, whereas its antimicrobial properties are shared by a number of phenothiazine analogues. This raises the possibility that its enantiomers or its inactive metabolite, the ring sulphoxide, may act as a lead compound in the future development of antimicrobial drugs to face the new challenges in infectious disease.</p>
</abstract>
<kwd-group><kwd>antimicrobial</kwd>
<kwd>drug development</kwd>
<kwd>drug resistance</kwd>
<kwd>QT prolongation</kwd>
<kwd>thioridazine</kwd>
<kwd>tuberculosis</kwd>
</kwd-group>
</article-meta>
</front>
</pmc>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaSubSaharaV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002D55 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 002D55 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= SidaSubSaharaV1 |flux= Pmc |étape= Corpus |type= RBID |clé= PMC:2203271 |texte= Thioridazine: resurrection as an antimicrobial agent? }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:17764469" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a SidaSubSaharaV1
![]() | This area was generated with Dilib version V0.6.32. | ![]() |